ERBB2 and breast carcinoma: The addition of dasatinib to trastuzumab and paclitaxel as a first line treatment of metastatic HER2+ breast cancer was well tolerated, with no grade 4 toxicities, and showed clinical activity (ORR=89 %) [47].